B668 - Adiponectin as a biomarker in pharmacoepidemiology and as a biomarker in the wide human clinical phenome - 26/06/2008

B number: 
Principal applicant name: 
Prof Ian Day (University of Bristol, UK)
Prof Lyle Palmer (Not used 0, Not used 0), Vilmundur Gudnason (Not used 0, Not used 0), Shah Ebrahim (Not used 0, Not used 0), John Beilby (Not used 0, Not used 0), Prof George Davey Smith (University of Bristol, UK), Prof Craig Pennell (Not used 0, Not used 0), Prof Yaov Ben-Schlomo (University of Bristol, UK), Prof Debbie A Lawlor (University of Bristol, UK), Dr Nic Timpson (University of Bristol, UK), Santiago Rodriguez (University of Bristol, UK), Prof Naveed Sattar (University of Glasgow, UK), Dr Susan Ring (University of Bristol, UK)
Title of project: 
Adiponectin as a biomarker in pharmacoepidemiology; and as a biomarker in the wide human clinical phenome
Proposal summary: 

Adiponectin is the most highly expressed adipocyte protein and is readily measurable in serum. It

has been extensively studied in the context of obesity, diabetes and metabolic syndrome and has

been clearly shown to have a direct role in the pathogenesis of diabetes. Being negatively

correlated with fat mass and acting as an insulin sensitizer, it represents one critical link between

fat mass and diabetes. It also has directly anti-inflammatory actions. Vascular disease and other

consequences of diabetes are among the most major diseases of our era in the developed and

developing worlds. This then states the general prominence of the protein. This proposal concerns

the biomarker potentials of adiponectin ranging beyond its pathogenic role in diabetes. We focus

on its potential as a pharmacoepidemiological marker and on its relationships to many other

facets of the clinical phenome.

Date proposal received: 
Thursday, 26 June, 2008
Date proposal approved: 
Thursday, 26 June, 2008
Primary keyword: